MEDICINOVA INC. - COMMON STOCK

MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

08 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference

21 Apr 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

20 Apr 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

12 Apr 2022 23:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

11 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

07 Apr 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea

17 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest

15 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal

28 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

22 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea

01 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada

31 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

27 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe

26 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

13 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

10 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology

22 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

11 Nov 2021 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting

10 Nov 2021 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology

03 Nov 2021 19:30:00 By Nasdaq GlobeNewswire